Five Leading Pharmaceutical Companies Join Hands with Alibaba Health to Build a New Digital Healthcare Ecosystem
Five Leading Pharmaceutical Companies Join Hands with Alibaba Health to Build a New Digital Healthcare EcosystemOn September 12th, five well-known pharmaceutical companies, including HuiZh China, Qilu Pharmaceutical, Taiji Group, Dain Pharmaceutical, and Jiangzhong Group, gathered in Hangzhou to sign strategic cooperation agreements with Alibaba Health's online pharmacy. This collaboration will focus on multiple areas, including online retail, category expansion, new drug launches, and disease education, to comprehensively implement digital healthcare service cooperation...
Merck: Technological Innovation Drives Pharmaceutical Development, Supporting Global Patient Health
Merck: Technological Innovation Drives Pharmaceutical Development, Supporting Global Patient HealthThe pharmaceutical industry is a blue ocean brimming with challenges and opportunities, where technological innovation is the driving force behind progress and development. From new drug development to therapeutic breakthroughs, from personalized medicine to the rise of digital healthcare, technological advancements are profoundly shaping the pharmaceutical landscape...
A Wake-up Call for Research Integrity: Image Duplication Controversy in a Paper from China Pharmaceutical University
A Wake-up Call for Research Integrity: Image Duplication Controversy in a Paper from China Pharmaceutical UniversityIn recent years, academic integrity has increasingly become a focal point in the academic community. Publishing in academic journals signifies that research findings will undergo peer review and scrutiny from the scientific community, making it crucial for researchers' reputation and academic advancement...
Shanghai releases three major action plans in the field of biopharmaceuticals, with nearly 5 million square meters of factory buildings to be built
Shanghai, which has listed biopharmaceuticals as one of the three leading industries, has also released new industrial policies.At the opening ceremony of the 2023 Shanghai International Biomedical Industry Week held on the afternoon of the 16th, Shanghai released three major action plans for the three cutting-edge tracks of synthetic biology, gene therapy, and medical robotics...
During the Shanghai International Biopharmaceutical Industry Week, experts, scholars, and corporate executives discussed these topics
On October 16th, the opening event of the 2023 Shanghai International Biopharmaceutical Industry Week was held at the Zhangjiang Science Hall in Shanghai.At the event site, discussions were held among participants on topics such as innovation internationalization and industrial internationalization, industrial agglomeration development, and the establishment of ecological service systems...
Focus on the international biomedicine frontier race track: the type 2 diabetes living biological drug pipeline was officially launched in Zhangjiang Pharmaceutical Valley
On October 8, under the witness of the General Health Professional Committee of Shanghai Modern Service Industry Federation, Zhangjiang Living diabetes II (T2D) Living Biological Drug (LBP) pipeline of Zhangjiang Living Biological Drug Research and Development Center was officially launched. Jian Danian, Vice President of Shanghai Modern Service Industry Federation, stated that the federation will continue to closely adhere to Shanghai's modern industrial system and introduce more high-level technology enterprises to Pudong and Zhangjiang...
Notice of Clinical Trial Approval for Recombinant Human Adenovirus 5 Injection of Shanghai Pharmaceuticals Group Co., Ltd. Restructuring
Recombinant human adenovirus type 5 injection (trade name: Ankrui) is an oncolytic adenovirus anti-tumor drug that contains recombinant adenoviruses that can specifically replicate in tumor cells, cause tumor cell damage, lysis, and further activate immune responses to exert anti-tumor effects. Ankeri was approved for marketing in China in 2005, with an approved indication for advanced nasopharyngeal carcinoma...